Novartis Animal Health Inc. has completed an agreement with Luitpold Pharmaceuticals, Inc. that grants marketing rights for Adequan® Equine to Novartis in all major equine markets outside the U.S. The first launch of Adequan® Equine by Novartis will…
Novartis Animal Health has announced that it will begin marketing and distributing Adequan Equine in the UK from January 2011.
According to the company, Adequan Equine offers equine veterinarians a proven intramuscular treatment option for equine degenerative…
Novartis Animal Health has announced that it has assumed marketing responsibilities for the joint health supplement Cosequin in the United Kingdom and Ireland.
Cosequin, which contains glucosamine and chondroitin sulfate, is available in a range of presentations…
Novartis Animal Health has assumed marketing responsibilities for the joint health supplement Dasuquin in the United Kingdom and Ireland.
Dasuquin is a veterinary formulation developed to deliver advanced cartilage support in dogs. It contains a combination…